Sjogren's Syndrome
Recent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 6 clinical trials with recent milestones (1 completed or reporting results).
Clinical MilestonesViewHide
- 2026-08-19A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-severe Systemic Disease ActivityPrimary completion
- 2025-12-31Effectiveness of Belimumab After Rituximab in Resistant Primary Juvenile Sjogren's SyndromePrimary completion
- 2025-12-01Efficacy, Immunogenicity and Safety of Recombinant Vaccine Against Herpes Zoster (RZV or SHINGRIX®) in Patients With Autoimmune Rheumatic DiseasesPrimary completion
- 2028-01-01ClinicalA Phase 2, Open Label Study of Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's SyndromeWithdrawn
- 2026-08-19ClinicalA Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-severe Systemic Disease ActivityPrimary completion
- 2026-04-28ClinicalA Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren's SyndromeTerminated
- 2025-12-31ClinicalEffectiveness of Belimumab After Rituximab in Resistant Primary Juvenile Sjogren's SyndromePrimary completion
- 2025-12-18ClinicalSafety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome; a Phase Ib-IIa Placebo-controlled Clinical Trial and Associated Mechanistic StudiesResults posted
- 2025-12-01ClinicalEfficacy, Immunogenicity and Safety of Recombinant Vaccine Against Herpes Zoster (RZV or SHINGRIX®) in Patients With Autoimmune Rheumatic DiseasesPrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Sjogren's Syndrome3
- Autoimmune Diseases1
- Fibrosis1
- Lupus Erythematosus, Systemic1
- Lymphoma, Large B-Cell, Diffuse1
- Receptors, Chimeric Antigen1
- Respiratory Distress Syndrome1
- Salivary Glands1
Leading journals2
- Frontiers in immunology2
- Immunology letters1
Leading researchers8
- Cao W1
- Chen S1
- Feng Y1
- Jiang X1
- Kroese FGM1
- Li L1
- Lin X1
- Ma D1
Affiliations (unnormalised)6
- Department of Neurology and Institute of Neurology1
- Leiden University Medical Center1
- Peking University Third Hospital1
- Ruijin Hospital1
- School of Chinese Medicine1
- Shanghai Institute of Hematology1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.